title: [A Patient with Three-Year Relapse-Free Survival after Surgical Resection for Lung and Liver Metastases of Cholangiocarcinoma].
abstract: We report of a patient with 3-year relapse-free survival after surgical resection for lung and liver metastases of distal cholangiocarcinoma (DCC). A quinquagenarianman was taken to a local hospital in October 2009 for yellow urine. He was diagnosed with DCC and was referred to our hospital for surgery. Pancreaticoduodenectomy was performed, and there was no residual tumor on histological examination. He did not receive any adjuvant therapy. One year 7 months after surgery, an isolated lung metastasis was identified on CT and was surgically removed. Six months after resection of the lung metastasis, a solitary liver metastasis was detected. Although systematic chemotherapy (gemcitabine plus S-1; 2 weeks treatment, 1 week drug free) was administered, the treatment was abandoned because of grade 3 (CTCAE v4.0) of skin disorders during the third course. Partial resection of the liver was performed in April 2012. Alternate-day treatment with S-1 was performed after resection of liver metastasis and is ongoing without adverse events. He has survived for more than 3 years without recurrence after liver resection. In this case of DCC metastasis, prognosis improved with surgical resection.
authors.affiliation: Dept. of Surgery, Tohoku University School of Medicine.
authors.forename: Shuichi
authors.initials: S
authors.lastname: Aoki
authors.forename: Masamichi
authors.initials: M
authors.lastname: Mizuma
authors.forename: Motoki
authors.initials: M
authors.lastname: Oyauchi
authors.forename: Hiroshi
authors.initials: H
authors.lastname: Yoshida
authors.forename: Ryo
authors.initials: R
authors.lastname: Okada
authors.forename: Tomoya
authors.initials: T
authors.lastname: Abe
authors.forename: Naoaki
authors.initials: N
authors.lastname: Sakata
authors.forename: Kei
authors.initials: K
authors.lastname: Nakagawa
authors.forename: Hiroki
authors.initials: H
authors.lastname: Hayashi
authors.forename: Takanori
authors.initials: T
authors.lastname: Morikawa
authors.forename: Fuyuhiko
authors.initials: F
authors.lastname: Motoi
authors.forename: Takeshi
authors.initials: T
authors.lastname: Naitoh
authors.forename: Yoshinori
authors.initials: Y
authors.lastname: Okada
authors.forename: Michiaki
authors.initials: M
authors.lastname: Unno
mesh_terms: D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D001650:Bile Duct Neoplasms / Q000188:drug therapy / Q000473:pathology* / Q000601:surgery; D018281:Cholangiocarcinoma / Q000188:drug therapy / Q000473:pathology* / Q000601:surgery; D003841:Deoxycytidine / Q000008:administration & dosage / Q000031:analogs & derivatives; D004338:Drug Combinations; D006498:Hepatectomy; D006801:Humans; D008113:Liver Neoplasms / Q000188:drug therapy* / Q000556:secondary / Q000601:surgery; D008175:Lung Neoplasms / Q000556:secondary* / Q000601:surgery; D008297:Male; D008875:Middle Aged; D010094:Oxonic Acid / Q000008:administration & dosage; D016577:Pancreaticoduodenectomy; D012008:Recurrence; D005641:Tegafur / Q000008:administration & dosage; D000093542:Gemcitabine
chemical_list: D004338:Drug Combinations; D003841:Deoxycytidine; C079198:S 1 (combination); D005641:Tegafur; D010094:Oxonic Acid; D000093542:Gemcitabine